Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAnanda, Sumitra-
dc.contributor.otherHong, Wei-
dc.contributor.otherRichardson, Gary-
dc.contributor.otherLombard, Janine-
dc.contributor.otherGoss, Geraldine-
dc.contributor.otherMileshkin, Linda-
dc.contributor.otherSteer, Christopher-
dc.contributor.otherO’Broin Lennon, Anne Marie-
dc.contributor.otherMcNally, Orla-
dc.contributor.otherDouville, Christopher-
dc.contributor.otherPopoli, Maria-
dc.contributor.otherPtak, Janine-
dc.contributor.otherSilliman, Natalie-
dc.contributor.otherDobbyn, Lisa-
dc.contributor.otherPapadopoulos, Nicholas-
dc.contributor.otherKinzler, Kenneth-
dc.contributor.otherVogelstein, Bert-
dc.contributor.otherTie, Jeanne-
dc.contributor.otherGibbs, Peter-
dc.description.abstractPatients with epithelial ovarian cancer (EOC) often relapse despite surgery and chemotherapy. Current prognosis estimates, based on FIGO staging molecular features lack precision. Standard of care for stage I III EOC is 6 cycles of adjuvant chemotherapy, which may include 3 cycles of neoadjuvant treatment. Many treated patients do not benefit from chemotherapy because they had no residual disease post operatively or because treatment did not eradicate disease that was present. Studies in multiple solid tumor types have demonstrated that after curative intent surgery detectable ctDNA a marker of minimal residual disease (MRD) predicts a very high risk of recurrence. Our primary aim was to explore the association between detectable ctDNA following debulking of primary EOC and recurrence free survival (RFS). Secondary aims included exploring the relationship between ctDNA and RFS at EOC diagnosis, following neoadjuvant therapy and post adjuvant chemotherapy. In a prospective cohort of patients with epithelial ovarian cancer analysed for ctDNA Neoadjuvant therapy cohort - ctDNA was detectable pre treatment in most patients. Most pre treatment ctDNA ve patients remained ctDNA ve despite chemotherapy. Post cancer cytoreduction surgery cohort - ctDNA was more likely to be detected in patients with stage III/IV disease, those with residual disease, and those without a BRCA mutation. ctDNA detection was associated with 2 year RFS. Post adjuvant chemotherapy cohort - ctDNA detection was associated with a trend to inferior 2 year RFS.en_US
dc.subjectEpithelial Ovarian Canceren_US
dc.subjectDetectable ctDNAen_US
dc.subjectMinimal Residual Diseaseen_US
dc.subjectRecurrence Free Survivalen_US
dc.subjectNeoadjuvant Therapyen_US
dc.subjectPost Adjuvant Chemotherapyen_US
dc.titleCirculating Tumor DNA (ctDNA) as a marker of residual disease and recurrence risk in resected stage I IV epithelial ovarian cancer (EOC).en_US
dc.typeConference Posteren_US
dc.description.affiliatesWalter and Eliza Hall Institute of Medical Research, Australiaen_US
dc.description.affiliatesPeter MacCallum Cancer Centre, Australiaen_US
dc.description.affiliatesWestern Health, Australiaen_US
dc.description.affiliatesDepartment Of Medicine, University of Melbourne, Australiaen_US
dc.description.affiliatesCabrini Health, Australiaen_US
dc.description.affiliatesNewcastle Private, Australiaen_US
dc.description.affiliatesJohn Hopkins University, School of Medicine, USAen_US
dc.description.affiliatesMonash Medical Centre, Australiaen_US
dc.description.affiliatesEastern Health, Australiaen_US
dc.description.affiliatesMercy Hospital for Women, Heidelberg, Australiaen_US
dc.description.affiliatesBorder Medical Oncology, Australiaen_US
dc.description.affiliatesRoyal Women’s Hospital Parkville, Australiaen_US
dc.type.studyortrialProspective Observational Studyen_US
dc.description.conferencenameEpworth HealthCare Research Month 2023en_US
dc.description.conferencelocationEpworth Research Institute, Victoria, Australiaen_US
Appears in Collections:Research Month

Files in This Item:
File Description SizeFormat  
ASCO Poster ctDNA Ovary Final 01082023 Epworth Research Week _SAnanda.pdf543.35 kBAdobe PDFThumbnail

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.